About the Course
Introduction
This CLE webinar will closely examine the recent proclamation issued by the Trump administration imposing 100% tariffs on imported patented pharmaceuticals and related ingredients under Section 232 of the Trade Expansion Act of 1962 (Section 232). The panel will discuss the complex tiered rate structure and address the impact these changes will have on the pharmaceutical industry, including cost increases and potential supply chain issues. The panel will also offer best practices for compliance.
Description
The Trump administration recently issued a proclamation imposing sweeping tariffs on patented pharmaceuticals and related ingredients under Section 232, citing threats to national security and the economy as the reason.
Beginning as early as July 31, 2026 for certain large pharmaceutical companies and becoming widely effective on Sept. 29, 2026 for all covered entities, a baseline tariff of 100% will be imposed on imports of patented pharmaceuticals, biologics, and associated ingredients impacting pharmaceutical manufacturers, importers, and supply chain participants.
The proclamation establishes a complex, multi-tiered rate structure and allows for certain company, country, and product-specific tariff reductions and exemptions—all with the purpose of pushing companies toward domestic manufacturing and pricing concessions.
Counsel with clients in the pharmaceutical and life sciences industries should have a clear understanding of the new tariff structure and how it will impact their clients, including cost increases, supply chain disruptions, and changes in business practices.
Listen as our expert panel closely examines the recent proclamation and the new tariff structure. The panel will address the impact these changes will have on the pharmaceutical industry and discuss next steps that counsel and clients should be taking now.
Presented By
Ms. Gustafson focuses her practice on U.S. customs and international trade matters. She advises multinational clients in a wide range of customs and trade areas including customs valuation, classification, country of origin, preferential trade programs, mergers and acquisitions due diligence, import compliance, reconciliation, duty mitigation, compliance reviews, and disclosures. Prior to joining the firm, Ms. Gustafson served as a customs and international trade consultant for multinational professional services organizations. She brings extensive experience in leading valuation planning and duty mitigation strategies, preparing and submitting binding ruling requests to CBP, as well as representing clients in CBP audits and inquiries. Ms. Gustafson received her Customs broker license in 2021.
Ms. Navarro has extensive experience advising companies, multinationals, trade associations and governments on customs and trade law and policy, trade compliance matters, free trade negotiations, litigation and legislation. She helps clients resolve trade issues before U.S. Customs and Border Protection, Office of the US Trade Representative, Department of Commerce, U.S. Congress and the Court of International Trade. Ms. Navarro advises clients on complex customs and trade issues in the United States and numerous countries, before foreign trade and customs agencies, routinely guiding clients through problem identification, risk evaluation and efficient resolution strategies. Her advisory services include tariff classification, customs valuation, country of origin determination and labeling, trade preference programs, free trade agreements and comprehensive trade compliance strategies. She also works closely with clients in developing and enhancing forced labor compliance programs, conducting risk assessments and mock audits, as well as in responding to forced labor enforcement actions, including Requests for Information and detentions.
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
-
Date + Time
- event
Thursday, July 16, 2026
- schedule
1:00 PM ET/10:00 AM PT
I. Introduction
A. Presidential authority under Section 232
II. The proclamation
A. Purpose
B. Covered entities
C. Key definitions
D. Tiered rate structure
E. Exemptions
III. Next steps for counsel and clients
A. Risk assessment
B. Supply chain review
C. Other
IV. Key takeaways
The panel will review these and other important issues:
- Under what authority are the new tariffs imposed?
- What is the purpose behind the proclamation?
- How will the complex multi-tiered rate structure impact covered entities in the pharmaceutical industry?
- What should counsel and their covered clients be doing to prepare for compliance?
Related Courses
100% Tariffs Impacting the Pharmaceutical Industry: Section 232, Complex Multi-Tiered Rate Structure, Exemptions
Thursday, July 16, 2026
1:00 PM ET/10:00 AM PT
